Prenetics Global Limited (NASDAQ: PRE) is a Healthcare company in the Medical - Diagnostics & Research industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
Latest market price
18.13
-0.13-0.71%
TA
Loading chart...
Snapshot
| Index | - | P/E | - | EPS (ttm) | -4.58 | Insider Own | 7.40% | Shs Outstand | 17.00M | Perf Week | -2.04% |
| Market Cap | 310.43M | Forward P/E | - | EPS next Y | -1.84 | Insider Trans | 0.00% | Shs Float | 12.63M | Perf Month | 2.30% |
| Enterprise Value | 254.87M | PEG | 0.20 | EPS next Q | -0.48 | Inst Own | 12.41% | Short Float | 5.27% | Perf Quarter | 15.06% |
| Income | -71.12M | P/S | 2.73 | EPS this Y | 16.81% | Inst Trans | - | Short Ratio | 2.90 | Perf Half Y | 3.11% |
| Sales | 113.75M | P/B | 2.56 | EPS next Y | 51.71% | ROA | -40.52% | Short Interest | 665.82K | Perf YTD | 15.94% |
| Book/sh | - | P/C | - | EPS next 5Y | - | ROE | -46.74% | 52W High | 23.46 -22.73% | Perf Year | 131.73% |
| Cash/sh | - | P/FCF | - | EPS past 3/5Y | - | ROIC | -25.54% | 52W Low | 7.13 154.32% | Perf 3Y | 73.90% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | 91.99% 7.20% | Gross Margin | 58.32% | Volatility | 6.49% 10.25% | Perf 5Y | -83.73% |
| Dividend TTM | - | EV/Sales | 2.24 | EPS Y/Y TTM | -25.82% | Oper. Margin | -33.69% | ATR (14) | 1.70 | Perf 10Y | - |
| Dividend Ex-Date | Feb 17, 2016 | Quick Ratio | 4.60 | Sales Y/Y TTM | 270.97% | Profit Margin | -62.45% | RSI (14) | 46.65 | Recom | 2.00 |
| Dividend Gr. 3/5Y | -35.09% -21.51% | Current Ratio | 5.15 | EPS Q/Q | -70.00% | SMA20 | -4.99% | Beta | 0.21 | Target Price | 35.50 |
| Payout | 0.00% | Debt/Eq | 0.00 | Sales Q/Q | 111.76% | SMA50 | -5.86% | Rel Volume | 0.30 | Prev Close | 18.26 |
| Employees | 98 | LT Debt/Eq | 0.02 | Earnings | Aug 18 | SMA200 | 3.93% | Avg Volume | 230.48K | Price | 18.13 |
| IPO Date | Jul 16, 2021 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -33.77% -0.13% | Net Debt/EBITDA | 1.08 | Volume | 69,593 | Change | -0.71% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jul-15-26 | Reiterated | Lake Street | $29 → $35 | |
| Feb-11-26 | Initiated | Roth Capital | Buy | $36 |
Latest News
Aug-07-26
Aug-07-2608:30AM
Aug-04-26
Jul-23-26
06:22AM
Jul-15-26
Jul-14-26
Jul-14-2602:01PM
01:35PM
Jul-09-26
Jul-09-2607:00AM
Jun-30-26
Jun-30-2609:30AM
Jun-16-26
Jun-16-2609:11AM
Company
As an investment holding company, Prenetics Global Limited specializes in providing diagnostic and genetic testing services. Its comprehensive product line features CircleDNA, a consumer-oriented genetic analysis solution, and the Circle HealthPod, an advanced health monitoring device. The Circle HealthPod facilitates rapid COVID-19 detection through nucleic acid amplification technology, suitable for both professional point-of-care and personal at-home use. Additionally, the company offers ColoClear, a non-invasive FIT-DNA screening test for colorectal cancer, and Circle SnapShot, a readily available at-home blood testing kit. Other diagnostic solutions in their portfolio include Circle Medical, Circle One, and F1x/Fem. Prenetics Global Limited was founded in 2014 and maintains its headquarters in Quarry Bay, Hong Kong.
Ownership
Total institutional ownership12.41%
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 115 | 92 | 31 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 48 | 44 | 15 | — | — | — | — | — | |
| Gross Profit | 66 | 49 | 15 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 96 | 80 | 55 | — | — | — | — | — | |
| Research and Development | 4 | 5 | 11 | — | — | — | — | — | |
| Other Operating Expense | 4 | 2 | -2 | — | — | — | — | — | |
| Operating Income | -38 | -38 | -48 | — | — | — | — | — | |
| Interest Expense | 0 | 0 | 0 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -36 | 2 | -9 | — | — | — | — | — | |
| Net Income Before Taxes | -73 | -36 | -58 | — | — | — | — | — | |
| Income Taxes | 0 | 0 | -8 | — | — | — | — | — | |
| Consolidated Net Income | -70 | -38 | -46 | — | — | — | — | — | |
| Net Income From Continuing Operations | -73 | -36 | -50 | — | — | — | — | — | |
| Net Income | -70 | -38 | -46 | — | — | — | — | — | |
| EPS (Recurring) | -4.58 | -2.68 | -3.64 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -4.58 | -2.68 | -3.64 | — | — | — | — | — | |
| EPS (Diluted) | -4.58 | -2.68 | -3.64 | — | — | — | — | — | |
| EBITDA | -53 | -32 | -52 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 2.68 | 2.40 | 2.43 | — | — | — | — | — | |
| Gross Margin | 57.39 | 53.26 | 48.39 | — | — | — | — | — | |
| Operating Margin | -33.04 | -41.30 | -154.84 | — | — | — | — | — | |
| Net Margin | -60.87 | -41.30 | -148.39 | — | — | — | — | — | |
| Shares Outstanding | 17 | 14 | 13 | — | — | — | — | — | |
| Market Capitalization | 308 | 221 | 75 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Leogrande Hudson Blake | Director | Aug 04 '26 | Option Exercise | 0.00 | 2,001 | 0 | 4,001 | Aug 05 |
| Leogrande Hudson Blake | Director | Jul 04 '26 | Option Exercise | 0.00 | 2,000 | 0 | 2,000 | Jul 07 |
| Cheng Yin Pan | Director | Jun 15 '26 | Option Exercise | 0.00 | 15,873 | 0 | 59,051 | Jun 16 |
| VANDERVEEN DAVID | Director | Jun 15 '26 | Option Exercise | 0.00 | 15,625 | 0 | 45,249 | Jun 16 |
| Desmet Laurie | EVP & COO, PartnerRe Ltd | Dec 21 '15 | Sale | 139.11 | 710 | 98,770 | 38,386 | Dec 22 |
| Hanratty Judith | Director | Oct 29 '15 | Sale | 139.30 | 2,336 | 325,405 | 5,601 | Nov 02 |
| SAUTTER REMY | Director | Sep 17 '15 | Option Exercise | 71.12 | 5,282 | 375,656 | 24,866 | Sep 18 |
| SAUTTER REMY | Director | Sep 17 '15 | Sale | 138.46 | 5,282 | 731,339 | 19,584 | Sep 18 |
| SAUTTER REMY | Director | Sep 16 '15 | Option Exercise | 69.38 | 15,613 | 1,083,153 | 30,352 | Sep 18 |
| SAUTTER REMY | Director | Sep 16 '15 | Sale | 138.46 | 15,613 | 2,161,844 | 19,584 | Sep 18 |
| ZWIENER DAVID K | President & CEO PartnerRe Ltd. | Jun 15 '15 | Option Exercise | 130.50 | 978 | 127,629 | 24,003 | Jun 17 |
| SAUTTER REMY | Director | Jun 15 '15 | Option Exercise | 78.33 | 978 | 76,604 | 17,668 | Jun 17 |
| MONTUPET JEAN PAUL L | Director | Jun 15 '15 | Option Exercise | 78.28 | 1,137 | 89,001 | 17,054 | Jun 17 |
| MENDOZA ROBERTO G | Director | Jun 15 '15 | Option Exercise | 130.50 | 1,297 | 169,259 | 8,808 | Jun 17 |
| Walker Theodore C | President & CEO, PartnerRe NA | Feb 05 '15 | Option Exercise | 60.28 | 36,629 | 2,208,120 | 35,866 | Feb 09 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.